Business
Final Results
Final Results.
About this update from Theracryf Plc
[{"type":"text","content":"\n\nEvgen Pharma plc\n (the \"Company\")\n \nFull year Results\n7 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces its audited results for the year ended 31 March 2023.\nOperational summary\n\n· Substantial out-licensing deal signed with STALICLA SA for neurodevelopmental disorders and schizophrenia with total milestones of $160.5m, double digit royalties\n\n\no $0.5m milestone payment received from STALICLA\no Up to $5.5m in further milestones expected within 2024\n\n\n· Phase I/Ib healthy volunteer study of new SFX-01 formulation completed during the financial year:\n\n\no Positive safety and pharmacokinetic read out announced on 22 March 2023\no No serious adverse events, total drug and active metabolites detected in the range seen in lab experiments which show significant activity in vitro\n\n\n· First phase of glioblastoma trial expected to commence in 2024 and to be conducted as an Investigator Sponsored Study at the Erasmus University Medical Centre, Rotterdam\n· Grant applications submitted to Netherlands authorities to fund glioblastoma pre-clinical and clinical work and positive regulatory advice received to date regarding the trial\n· Further progress with the University of Manchester collaboration investigating potential use of SFX-01 in breast cancer patients with resistance to CDK4/6 inhibitors\n· Continued collaboration with University La Sapienza di Roma on potential radio-sensitisation properties of SFX-01\n· Emerging evidence of radio-sensitisation demonstrated for SFX-01 in vitro, as published at ESMO rare diseases conference, March 2023\n· Continued collaboration with University of Michigan, to investigate the potential anti-tumour effects of SFX-01 in colorectal cancer\n· CFO, Richard Moulson, to retire at AGM in late July. Search for replacement well underway\n\n\n \n\n\nOutlook\n\n\n· Clinical trials in Autism Spectrum Disorder and Glioblastoma ...